What is Bloom Burton’s Forecast for TSE:MBX FY2027 Earnings?

Microbix Biosystems Inc. (TSE:MBX) – Research analysts at Bloom Burton lowered their FY2027 earnings estimates for shares of Microbix Biosystems in a research report issued to clients and investors on Friday, May 16th. Bloom Burton analyst D. Martin now expects that the company will earn $0.04 per share for the year, down from their previous forecast of $0.05. The consensus estimate for Microbix Biosystems’ current full-year earnings is $0.02 per share.

Microbix Biosystems Stock Performance

Shares of MBX opened at C$0.35 on Monday. The company’s fifty day moving average is C$0.38 and its 200-day moving average is C$0.39. Microbix Biosystems has a 12 month low of C$0.29 and a 12 month high of C$0.55. The firm has a market cap of C$46.10 million, a price-to-earnings ratio of 13.33 and a beta of 0.34. The company has a quick ratio of 5.57, a current ratio of 7.15 and a debt-to-equity ratio of 22.61.

Insider Transactions at Microbix Biosystems

In related news, Senior Officer Mark Adrian Luscher sold 70,750 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of C$0.43, for a total value of C$30,295.15. 14.00% of the stock is currently owned by company insiders.

About Microbix Biosystems

Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.